T. Rowe Price Investment Management
NVCR icon

T. Rowe Price Investment Management’s NovoCure NVCR Stock Holding History

T. Rowe Price Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-927,382
Closed -$10.1M – 786
2026
Q1 		$10.1M Buy
927,382
+924,239
+29,406% +$11.5M 0.01% 536
2025
Q4 		$41K Sell
3,143
-942,283
-100% -$12.1M ﹤0.01% 672
2025
Q3 		$12.2M Buy
945,426
+227,371
+32% +$3.04M 0.01% 546
2025
Q2 		$12.8M Buy
+718,055
New +$12.5M 0.01% 539
2025
Q1 		– Sell
-1,690,441
Closed -$50.4M – 687
2024
Q4 		$50.4M Sell
1,690,441
-1,115,692
-40% -$23.6M 0.03% 407
2024
Q3 		$43.9M Buy
2,806,133
+1,093,740
+64% +$19.8M 0.03% 422
2024
Q2 		$29.3M Buy
+1,712,393
New +$30.1M 0.02% 461
2023
Q3 		– Sell
-1,890,836
Closed -$78.5M – 587
2023
Q2 		$78.5M Buy
1,890,836
+312,351
+20% +$19.4M 0.05% 307
2023
Q1 		$94.9M Buy
1,578,485
+1,533,426
+3,403% +$123M 0.07% 268
2022
Q4 		$3.31M Buy
+45,059
New +$3.39M ﹤0.01% 530

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

T. Rowe Price Investment Management's NVCR Position: Q2 2026 in Review

T. Rowe Price Investment Management sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 927,382 shares — an estimated $10.1M sold.

T. Rowe Price Investment Management first reported a position in NVCR in Q4 2022 and held it in 10 quarters. The position peaked at $94.9M in Q1 2023. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • T. Rowe Price Investment Management reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 927,382 NovoCure shares in Q2 2026, an estimated $10.1M.
  • T. Rowe Price Investment Management first reported a position in NovoCure in Q4 2022 and held it in 10 quarters.
  • T. Rowe Price Investment Management's NovoCure position peaked at $94.9M in Q1 2023.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.